Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

AIM: Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study (NCT01765790) assessed the safety, tolerability, pharmacokinetics and antitumour activity of imalumab, an oxMIF inhibitor, in patients with advanced c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Niels, Ramanathan, Ramesh K., Sarantopoulos, John, Völkel, Dirk, Youssef, Ashraf, de Jong, Floris A., Tsimberidou, Apostolia Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444762/
https://www.ncbi.nlm.nih.gov/pubmed/32207164
http://dx.doi.org/10.1111/bcp.14289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444762/
https://www.ncbi.nlm.nih.gov/pubmed/32207164
http://dx.doi.org/10.1111/bcp.14289

Ejemplares similares